Kedrion Biopharma Supports the Rare Disease Community at the 75th Annual Bleeding Disorders Conference

Fort Lee, NJ, (Aug 21, 2023)Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, recently participated in the 75th Annual Bleeding Disorders Conference in National Harbor, Maryland.

At the conference, through a grant to the National Hemophilia Foundation, Kedrion supported the Plasminogen Deficiency Foundation in a roundtable for patients with Congenital Plasminogen Deficiency. The grant also provided travel assistance to patients who would otherwise be unable to attend. Kedrion team members, along with the Plasminogen Deficiency Foundation and other rare disease advocates, also hosted patients at an Ultra Rare Networking Hour.

For the medical community in attendance, Kedrion submitted five posters on subjects relating to research and treatment of Plasminogen Deficiency and other rare diseases including Thrombotic Thrombocytopenic Purpura (TTP) and Factor X Deficiency.

“It is our privilege to speak with patients who fight ultra-rare diseases and bleeding disorders. As a company dedicated to fighting rare diseases, our mission at Kedrion is to produce medicines that help patients fight those diseases,” said Bob Rossilli, Chief Commercial Officer at Kedrion. “Working with organizations like the Plasminogen Deficiency Foundation and the National Hemophilia Foundation helps to provide patients, families and caregivers with the resources that they need.”

Plasminogen Deficiency is an ultra-rare genetic condition that occurs when a person has a mutation in both copies of the gene for plasminogen. It causes ligneous (wood-like) growths on mucous membranes in various areas of the body. Through the Plasminogen Deficiency Foundation, those affected can connect with other patients and families, access resources on insurance and treatment, and connect with a community.

“Dealing with a rare disease can be scary and isolating,” commented Rebecca Bialas, Co-Founder of the Plasminogen Deficiency Foundation. “Education and resources, along with the support of an empathetic community can help alleviate some of this burden.”


About Kedrion Biopharma

Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries.

About the Plasminogen Deficiency Foundation

The Plasminogen Deficiency Foundation is a 501(c)(3) nonprofit whose mission is to advance the care and treatment of patients with plasminogen deficiency (PLGD) by promoting public awareness of the disease through education and advocacy, creating a community for those affected by PLGD, and supporting research to address the current knowledge gaps in plasminogen deficiency and support development of sustainable treatments.